CSIMarket
 


Phasebio Pharmaceuticals Inc.  (PHAS)
Other Ticker:  
 
 

PHAS's Net Income Growth by Quarter and Year

Phasebio Pharmaceuticals's Net Income results by quarter and year




PHAS Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -43.11 -30.38 -11.33
III Quarter September - -31.92 -25.14 -11.39
II Quarter June -16.67 -28.68 -28.14 -9.23
I Quarter March -11.14 -27.36 -14.91 -7.29
FY   -27.81 -131.07 -98.57 -39.24



PHAS Net Income second quarter 2022 Y/Y Growth Comment
Phasebio Pharmaceuticals Inc. in the second quarter 2022 recorded net loss of $ -16.67 millions.

According to the results reported in the second quarter 2022, Phasebio Pharmaceuticals Inc. achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Phasebio Pharmaceuticals Inc.' s Net Income no change of % ranks overall at the positon no. in the second quarter 2022.




PHAS Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Phasebio Pharmaceuticals's second quarter 2022 Net Income $ -16.67 millions PHAS's Income Statement
Phasebio Pharmaceuticals's second quarter 2021 Net Income $ -28.68 millions Quarterly PHAS's Income Statement
New: More PHAS's historic Net Income Growth >>


PHAS Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Phasebio Pharmaceuticals's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PHAS's II. Quarter Q/Q Net Income Comment
Recent accomplishment of -16.67 millions by Phasebio Pharmaceuticals Inc. look even more unfavourable considering the net loss -11.14 millions a quarter before.

Within Major Pharmaceutical Preparations industry Phasebio Pharmaceuticals Inc. achieved highest sequential Net Income growth. While Phasebio Pharmaceuticals's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PHAS's II. Quarter Q/Q Net Income Comment
II. Quarter 2022 results of -16.67 millions by Phasebio Pharmaceuticals Inc. come out even worse considering the net loss -11.14 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Phasebio Pharmaceuticals Inc. achieved highest sequential Net Income growth. While Phasebio Pharmaceuticals's Net Income growth quarter on quarter, overall rank is .


Phasebio Pharmaceuticals's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Net Income 12 Months Ending $ -102.84 $ -114.85 $ -131.07 $ -118.34 $ -111.56
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment


Phasebio Pharmaceuticals Inc. achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment


Phasebio Pharmaceuticals Inc. achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
PHAS's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for PHAS's Competitors
Net Income Growth for Phasebio Pharmaceuticals's Suppliers
Net Income Growth for PHAS's Customers

You may also want to know
PHAS's Annual Growth Rates PHAS's Profitability Ratios PHAS's Asset Turnover Ratio PHAS's Dividend Growth
PHAS's Roe PHAS's Valuation Ratios PHAS's Financial Strength Ratios PHAS's Dividend Payout Ratio
PHAS's Roa PHAS's Inventory Turnover Ratio PHAS's Growth Rates PHAS's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Jun 30 2022
Resmed Inc -0.02%$ -0.020 millions
Hanger inc.-0.41%$ -0.413 millions
Addus Homecare Corporation-2.99%$ -2.992 millions
Electromed Inc -4.14%$ -4.140 millions
Prestige Consumer Healthcare Inc -5.93%$ -5.932 millions
National Research Corporation-6.95%$ -6.954 millions
U S Physical Therapy Inc-12.68%$ -12.683 millions
Hologic Inc-14.90%$ -14.903 millions
Baxter International Inc -15.28%$ -15.282 millions
Bruker Corporation-15.33%$ -15.332 millions
Edwards Lifesciences Corporation-16.98%$ -16.977 millions
Hca Healthcare Inc -17.13%$ -17.127 millions
Davita Inc -18.92%$ -18.920 millions
Dexcom Inc -19.08%$ -19.078 millions
Moderna Inc -20.97%$ -20.971 millions
Pediatrix Medical Group Inc -22.48%$ -22.480 millions
Laboratory Corporation Of America Holdings-23.31%$ -23.312 millions
Talkspace Inc -24.37%$ -24.372 millions
Gilead Sciences Inc -25.18%$ -25.181 millions
Dentsply Sirona Inc -26.26%$ -26.263 millions
Sotera Health Company-28.62%$ -28.621 millions
Healthcare Services Group Inc -28.70%$ -28.698 millions
Tenet Healthcare Corp-30.35%$ -30.350 millions
Becton Dickinson And Company-31.24%$ -31.238 millions
Eli Lilly And Company-31.48%$ -31.485 millions
United Therapeutics Corporation-32.79%$ -32.793 millions
La Jolla Pharmaceutical Company-34.15%$ -34.155 millions
Idexx Laboratories Inc-34.86%$ -34.859 millions
Viemed Healthcare Inc -38.25%$ -38.250 millions
Royalty Pharma Plc-39.06%$ -39.065 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com